Stock comparison
Haemonetics
Novartis AG
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
HAE
Haemonetics
Market cap
$2.98B
Sector
Healthcare
NVS
Novartis AG
Market cap
$290.64B
Sector
Healthcare
Overall winner
Haemonetics HAE
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | HAE | NVS | Winner |
|---|---|---|---|
| Warren Buffett | 70B | 62C | HAE |
| Benjamin Graham | 85A | 69B | HAE |
| Philip Fisher | 60C | 53C | HAE |
| Peter Lynch | 54C | 35D | HAE |
| Joel Greenblatt | 31F | 46D | NVS |
| Charlie Munger | 54D | 69C | NVS |
| Terry Smith | 55D | 66B | NVS |
Side-by-side metrics
| Metric | HAE | NVS |
|---|---|---|
| Market cap | $2.98B | $290.64B |
| P/E (TTM) | 24.8x | 21.3x |
| EV/EBIT | 14.1x | 19.2x |
| ROIC (TTM) | 8.37% | 14.89% |
| Gross margin | 55.74% | 75.13% |
| Net margin | 7.29% | 24.31% |
| Revenue CAGR 5y | 7.65% | 5.66% |
| EPS CAGR 5y | 24.62% | -9.29% |
| Debt / Equity | 1.5x | 1.2x |
| Dividend yield | 0.0% | 3.12% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
HAE leads on
- EPS CAGR 5y24.62%vs -9.29%+138%
- EV/EBIT14.1xvs 19.2x+26%
- Revenue CAGR 5y7.65%vs 5.66%+26%
NVS leads on
- Dividend yield3.12%vs 0.0%+100%
- Market cap$290.64Bvs $2.98B+99%
- Net margin24.31%vs 7.29%+70%
- ROIC (TTM)14.89%vs 8.37%+44%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.